United States - English - NLM (National Library of Medicine)

geigy pharmaceuticals - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - injection, solution - 25 mg in 2 ml - depression : for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. initial dosage should be low and increases should be gradual and cautiously prescribed. the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the drug. the possibility of cross-sensitivity to other dibenzazepine compounds should be k

Canada - English - Health Canada

geigy pharmaceuticals, ciba-geigy canada ltd. - desipramine hydrochloride - tablet - 50mg - desipramine hydrochloride 50mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

geigy pharmaceuticals, ciba-geigy canada ltd. - pamidronate disodium - liquid - 3mg - pamidronate disodium 3mg - bone resorption inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amantadine hydrochloride, quantity: 100 mg - capsule, soft - excipient ingredients: titanium dioxide; glycerol; lecithin; sodium propyl hydroxybenzoate; yellow beeswax; partially hydrogenated soya oil; iron oxide red; gelatin; sodium ethyl hydroxybenzoate; hydrogenated soya oil; rape seed oil; maize starch; sorbitol; mannitol; ethyl acetate; butan-1-ol; shellac; industrial methylated spirit - parkinson's disease: idiopathic parkinson's disease; post encephalitic parkinsonism; symptomatic parkinsonism (e.g. following cns injury from carbon monoxide poisoning); arteriosclerotic parkinsonism; drug-induced extrapyramidal reactions. symmetrel can be given alone for initial therapy or combined with anticholinergic drugs or l-dopa (see "dosage and administration"). note: symmetrel is not indicated for the treatment of tardive dyskinesia. type a virus influenza: prophylaxis of respiratory tract illness caused by influenza type a. prophylaxis in non-immunized individuals (including children) for whom influenza may have serious consequences (e.g. persons with chronic respiratory disease of diabetes mellitus).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; carmellose sodium; magnesium stearate; colloidal anhydrous silica - epilepsy 1. complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation. 2. generalised tonic-clonic seizures 3. mixed seizure patterns incorporating the above. carbamazepine sandoz is suitable for monotherapy and combination therapy. carbamazepine sandoz is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see precautions). trigeminal neuralgia for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. ( carbamazepine sandoz is not a simple analgesic and is not intended for trivial facial pain or headache). mania and bipolar affective disorders treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; carmellose sodium - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - carbamazepine - chewable tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - carbamazepine - chewable tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - carbamazepine - oral suspension - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - diclofenac sodium - solution for injection - 25mg/1ml